key: cord-0283944-9vkvegla authors: Nandakishore, P.; Lui, M.; Prakash, R.; Gourneni, S.; Sukumaran, R.; Berman, J. M.; Iyer, S. A.; Glorioso, C. A. title: Deviations in Predicted COVID-19 cases in the US during early months of 2021 relate to rise in B.1.526 and its family of variants date: 2021-12-08 journal: nan DOI: 10.1101/2021.12.06.21267388 sha: d27d0af5f9cb495004fc70f03589cdbd24559cf8 doc_id: 283944 cord_uid: 9vkvegla Objective: To investigate the abrogation of COVID-19 case declines from predicted rates in the US in relationship to viral variants and mutations. Design: Epidemiological prediction and time series study of COVID-19 in the US by State. Setting: Community testing and sequencing of COVID-19 in the US. Participants: Time series US COVID-19 case data from the Johns Hopkins University CSSE database. Time series US Variant and Mutation data from the GISAID database. Main outcome measures: Primary outcomes were statistical modeling of US state deviations from epidemiological predictions, percentage of COVID-19 variants, percentage of COVID-19 mutations, and reported SARS-CoV-2 infections. Results: Deviations in epidemiological predictions of COVID-19 case declines in the North Eastern US in March 2021 were highly positively related to percentage of B.1.526 (Iota) lineage (p < 10e - 7) and B.1.526.2 (p < 10 - 8) and the T95I mutation (p < 10e - 9). They were related inversely to B.1.427 and B.1.429 (Epsilon) and there was a trend for association with B.1.1.7 (Alpha) lineage. Conclusion: Deviations from accurate predictive models are useful for investigating potential immune escape of COVID-19 variants at the population level. The B.1.526 and B.1.526.2 lineages likely have a high potential for immune escape and should be designated as variants of concern. The T95I mutation which is present in the B.1.526, B.1.526.2, and B.1.617.2(Delta) lineages in the US warrants further investigation as a mutation of concern. Since the middle of 2020 many variants of SARS-CoV-2 have emerged. The emergence 2 of these variants has led to second and third waves of COVID-19 cases in many 3 countries including the US, Britain, and India. These variants have claimed numerous 4 lives and are responsible for the overcrowding of hospitals and other healthcare services. 5 Each SARS-CoV-2 variant is characterized by mutations on the genome of SARS-CoV-2. 6 Some of these mutations impart advantages to the variants such as higher transmission 7 rates or escape from immunity from previous COVID-19 infection or vaccination. 8 Many epidemiological models predicted a decline in COVID-19 cases in the US in 9 February and March of 2021 from a combination of natural immunity and previous 10 infection [1] . Epidemiologists expected that this may be delayed by variants of 11 concern [1]. The B.1.1.7 (Alpha) lineage (UK origin) was amongst the most concerning 12 of the known variants in the US. The B.1.1.7 lineage was found to be 43 to 90% more 13 transmissible compared to the previous variants based on the use of social contact, 14 mobility data, and other demographic indicators of COVID-19 [2] . Consequently, 15 studies point out that the number of cases would be considerably higher compared to 16 what was observed in 2020, without fast-paced vaccine roll-out [1] [2](5,6). The B.1.1.7 17 variant (UK origin) had a significant decrease in neutralization, specifically among 18 populations aged above 55 [3] (9) . The B.1.1.7 variant does not appear to raise concerns 19 regarding the vaccine's efficacy in real world or antibody neutralization 20 studies [4] [5] (7, 8) . The US also had two variants that originated in California-B.1.429 21 and B.1.427 (Epsilon). These exhibit a 18.6-24% increase in transmission compared to 22 wild-type. B1.427 [6] specifically shows a 3-6 fold reduction in neutralizing titers of 23 vaccinated or convalescent individuals [7] . It can be expected that so long as 24 transmission rates are high, new variants will continue to emerge, and each must be 25 treated as a new threat with the potential to escape prior immunity. 26 Other variants of concern, which included the P.1 and P.2 (Zeta) lineages (Brazilian 27 origin) and the B.1.351 (Beta, S. African origin) were not in the US in significant 28 enough numbers to pose an immediate threat. Although, the B.1.351 variant has shown 29 potential for immune escape and therefore can reduce the efficiency of vaccines [3] (9) . 30 Despite the CDC and other epidemiological models predicting case declines in late 31 2020 and early 2021, the US saw continued cases in the winter and spring of 2021 in the 32 US with New York City as the epicenter (fig 1A, 5) . In addition, a new variant arising 33 from the Washington Heights area of New York was identified( [8] ). 34 We demonstrate that the predicted drop in cases in the US in February and March of 35 2021 was delayed predominantly by infections in the North Eastern US by variants that 36 originated in New York City, B.1.526 and B.1.526.2 [9] . We first explore the relationship 37 between the number of COVID-19 cases and prevalence of various variants and The COVID-19 variants data was sourced from the API of Outbreak.info [10] . 44 Outbreak.info aggregates data across scientific sources, though the API, daily 45 surveillance reports about lineages and mutations, countries, states, and counties from 46 GISAID Initiative [11] were extracted for analysis. In an effort to include the maximum 47 number of lineages, the data [12] Engineering (JHU CSSE) [12] . The state population origins from census data of the 51 United States Census Bureau in 2019 [13] . prevalence measure for each day hence the prevalence was averaged across all days in a 60 month. Prevalence data for each month was collected for all states then averaged for 61 each state over a month. Gaussian smoothing with a window of 7 days applied to the 62 time series of the variant data. The Gaussian smoothing reduced the effect of noise due 63 to spikes in the time series data. Varying the window for Gaussian smoothing from 3 to 64 10 days did not significantly alter the results. These spikes represent cumulative variant 65 case number data dumps on specific days hence they were a source of noise while 66 averaging prevalence over a single month. The ordinate is scaled close to 1 by dividing the number of COVID-19 cases per day 68 by the population of the state divided by a thousand. The order of magnitude of 69 COVID-19 cases had decreased almost by an order of magnitude post the second wave 70 of cases in December 2020 hence scaling the cases per day by state population per 71 thousand negated the disparity between the most and least populous states. Python's 72 Pandas [14] package is used to process the data. We use linear regression to estimate initial susceptible/infectious/recovered (SIR) 83 parameters. We solve SIR differential equations for the next day for each region, then 84 re-estimate the SIR parameters with that day's output and the lag-adjusted 85 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.12.06.21267388 doi: medRxiv preprint non-pharmaceutical interventions (NPIs). We then iterate each day until reaching the 86 end date. Total US cases are calculated from the sum of the cases for each state. Holidays are adjusted for by addition to beta. The algorithm has seven basic steps: • Linear regression including NPIs from Oxford database to estimate the initial SIR 90 parameter, β (infection-producing contacts per unit time). • Adjust the parameters to account for asymptomatic cases based on CDC 92 seroprevalence estimates [15] . • Employ a separate SIR model using the β estimated in step one for the next day 94 for each US state. • Feed the new β extracted from each SIR model into a linear regression model that 96 incorporates the NPIs from one week prior (accounting for 14-day lag time from 97 NPI to case reporting) to produce an NPI-adjusted β. • Repeat steps 2-4 each day, feeding in the previous days predicted NPI-adjusted β 99 until reaching the end date. • The total US cases are summed from the US state cases. The mathematical description of the ordinary differential equations (ODE) 105 implemented are: While SIR modeling is useful for accurate predictions, it is not sufficient, as it fails 107 to consider that the reproductive number, R 0 is not a constant and will vary by country, 108 region, and over time, as conditions and interventions change. This dynamic R 0 is often 109 described as R e (R ef f ective ). Additionally,the number of susceptible, infectious, and 110 recovered individuals also vary by region. Testing capacity and the relationship of 111 reported cases to actual cases also varies by region. Finally, initial infection dates are 112 regionally-specific, as SARS-CoV-2 originated in China, spread to other parts of Asia, 113 then to Europe, to the Americas and so on. Together, these regional-specificities require 114 that each region must be predicted separately with its own SIR model. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Relative importance analysis is a useful technique to determine the relative importance 122 of predictors when independent variables are correlated to each other. In our case, we 123 hope to know how the most influential lineage changed regarding COVID-19 infections 124 and deaths in each state. A relative importance analysis was performed using the 125 "relaimpo" package in R [13] . Each predictor was fitted with a simple linear regression 126 model to compare the R 2 -values, these uni-variate R 2 -values indicate what each 127 predictor alone can explain the response. The importance ranking was determined by 128 the uni-variate R 2 -values-values, the larger is the uni-variate R 2 -values, the more 129 important is the predictor. Besides the R 2 -values, we also used the p-value of coefficient 130 (p < 0.05) in each model to filter insignificant predictors before we rank the importance. 131 Therefore, it is possible that no candidate is significant in the models. In this way, we 132 can determine which lineage is the most influential regarding new COVID-19 cases or 133 deaths for each state and each month. All statistical analyses were conducted using R 134 version 4.0.1 (2020-06-06), and figures were produced using the ggplot2 package [16] . 135 1 Results The classical susceptible/infectious/recovered (SIR) model is a versatile tool to predict 137 the spread of infectious diseases. SIR models coupled differential equations which are 138 solved to forecast dynamics disease spread. As with any set of differential equations, 139 SIR models require a set of initial conditions for numerically solving them. 140 We built an SIR model to predict the number of cases in the United States. We used 141 US Center for Disease Control (CDC) antibody data to adjust for under-testing and 142 under-reporting. We also adjusted for Holiday travel and event related spikes by 143 systematically increasing beta. Figure 1A shows the observed number of cases and the 144 predicted number of cases according to the SIR model. Our model was highly accurate for predicting eight weeks out, with a MAE of 10%. 146 This is half the error rate of any model or ensemble on the CDC dashboard and was 147 able to predict for twice as far out (data not shown). In late-February 2021, cases abruptly deviated from the predicted trajectory ( Fig 149 1A ). Most active US cases starting at that time were clustered in the North Eastern US 150 on a gradient decreasing from New York City ( Fig 1C) . When we evaluated case 151 deviations by State, we found that cases only deviated from predictions in these North 152 Eastern US states ( Fig 1B) . Other states were almost uniformly following the 153 trajectory predicted by our mathematical model ( Fig 1C) . 154 We investigated which variants were predominant in the states that deviated from our 156 model and found that B.1.526 and B.1.526.2 became the predominant variants in New 157 York and neighboring New Jersey in mid-February (Fig 1D) , the same time that cases 158 began to deviate from our predictions ( Fig 1A) . To assess which lineages are influencing the changing case numbers in the US in January and February to being significant in March (Fig 2) . B.1.526.1 was also 165 significant (p < 2e −4 )( 2). We also observed that B.1.427 and B.1.429 lineages 166 (California origin) had a significant(p < 3e − 3 and p < 8e − 4) but inverse relationship 167 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.12.06.21267388 doi: medRxiv preprint to the number of cases as seen in (2) . These lineages are associated with smaller case 168 numbers consistent with the rapidly declining cases in California and the Pacific 169 Northwest (1C) . Surprisingly, the prevalence of the B.1.1.7 variant (UK origin) did not 170 show significance with rising case numbers (Fig 2) . B.1.1.7 did, however, associate with 171 new COVID-19 cases and deaths in the greatest number of states in March. 172 We examined most prevalent variants in various US states by relative importance These results have a broader implication beyond these variants. As new 228 SARS-CoV-2 variants emerge, it remains possible that these new variants will escape 229 immunity generated by infection with a prior variant, or acquired through vaccinations, 230 defying the predictions of pandemic models, and leading to increased case-counts in 231 regions with high expected immunity. Using regional deviations from highly accurate 232 predictions can rapidly identify regions with variants that are escaping immunity. The data used in this study are cross-sectional. Ideally we would be able to test whether 248 the B.1.526 lineages were reinfecting the same person after being infected with the 249 original strains. Additionally it would be ideal to have data on vaccination status and 250 type of vaccine in the people infected with viral lineages longitudinally. Unfortunately, 251 these data do not exist or are not accessible. We strongly encourage testing and 252 reporting of this data by hospital systems so that we can more clearly understand the 253 role of the variants on breakthrough cases. Another limitation of the study is delays in 254 reporting sequencing data to databases. Accurate lineage data is available only with a 255 three week delay. This means that we are delayed in understanding important 256 information for policy planning and hospital staffing. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.12.06.21267388 doi: medRxiv preprint dangerous one, geographically located variants like B.1.526 are a cause for concern since 262 they may escape notice due their limited presence. 263 In the future we hope to access longitudinal data to more directly assess the effect of 265 lineages and their mutations on breakthrough cases and reinfection. These mutations 266 need further study on their impact, particularly T95I. Lastly, we will soon hopefully be 267 vaccinated to high enough degrees in more countries to take a global approach to 268 looking at mutations, lineages, and vaccination. We also hope to map the biological . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; Figure 2 . OLS Regression analysis of average number of cases per thousand vs COVID-19 lineage prevalence. Right column represents regression analysis for January, center for February and left for March. States that have a prevalence of larger than 0.01 are labeled. The shaded blue region represents the error in the slope of the fit. The color each each data points represents the scale of the average number of cases. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.12.06.21267388 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; . Heatmap for all US: Each cell in the heatmap represents the ratio of mutationlineage case counts and lineage case counts. Data from January to the end of March has been used to generate the heatmaps. The Mutation-lineage count represents how many cases for a lineage contained a mutation. This ratio will always be less than 1 since the total number of mutation-lineage cases will be less than the total number of lineage cases. The darker shades in the heatmap represent higher counts of a mutation for a specific lineage. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.12.06.21267388 doi: medRxiv preprint 3 Appendix Table 2 . P-value and R 2 values for COVID-19-mutations. We studied the correlation between the prevalence of multiple Spike mutations and number of cases and results presented in figure 3 is for a small subset of mutations. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 11 . Influential variants causing deaths for the month of February. Each US State is presented as a hexagon. The circles represent cases in segments of 10000. The colors represent different variants. The deaths in the east coast is dominated by B.1.1.7 and in the west coast by B.1.427. B.2 is also responsible for deaths in the many of the mid-western states. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.12.06.21267388 doi: medRxiv preprint Emergence of sars-cov-2 b.1.1.7 lineage united states Sensitivity of infectious sars-cov-2 b.1.1.7 and b.1.351 variants to neutralizing antibodies Neutralization of sars-cov-2 lineage b.1.1.7 pseudovirus by bnt162b2 vaccine-elicited human sera Sars-cov-2 variant b.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19) The localized rise of a b.1.526 sars-cov-2 variant containing an e484k mutation in new york state. medRxiv B.1.526 sars-cov-2 variants identified in new york city are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv Ginger Tsueng Alaa Abdel Latif and the Center for Viral Systems Biology. outbreak Data, disease and diplomacy: Gisaid's innovative contribution to global health An interactive web-based dashboard to track covid-19 in real time U.s. census bureau. state population totals Data structures for statistical computing in python Burden and characteristics of COVID-19 in the united states during 2020 Relative importance for linear regression in r: The package relaimpo Rapid emergence and epidemiologic characteristics of the sars-cov-2 b.1.526 variant -new york city, new york We thank just about everybody.